SOX2 and cancer: In the entire cohort (N = 180), the AR + Sox2– phenotype was associated with decreased locoregional recurrence risk (HR = 0.36, 95% CI 0.22–0.62, p = 0.0056), improved DMFI (HR = 0.34, 95% CI 0.15–0.74, p = 0.0425, Figure 3A), improved DFI (HR = 0.35, 95% CI 0.21–0.56, p = 0.0018, Figure 3B), improved overall survival (HR = 0.51, 95% CI 0.34–0.76, p = 0.0074, Figure 3C), and decreased probabilities of cancer-related death (HR = 0.24, 95% CI 0.16–0.38, p = 0.0001, Figure 3D).